Aptagen, LLC
Thrombin (ID# 8194)
DNA
α-thrombin
Protein
123.1 nM (reported value)
Using T4 PNK (Stratagene) for 45 min at 37C in PNK buffer (Stratagene).
In the presence of different concentrations of aptamers (0–1500 nm), human a-thrombin (2.5 NIH units per mL; CellSystems) and UFH (0.01 UmL^-1; Liquemin, Roche) were incubated in assay buffer (1x PBS, pH 7.4,
3 mm MgCl2, 1 mg mL^-1 BSA) for 5 min at room temperature in a total volume of 100 uL.
37°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Human thrombin-specific, a promising therapeutic measure in the treatment of patients with arterial and venous thromboembolism.
5'-dGpdGpdTpdTpdGpdGpdTpdGpdTpdTpdGpdTpdTpdGpdGp-3'
15
4701.1
141300
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Müller, J., Wulffen, B., Pötzsch, B., & Mayer, G. (2007). Multidomain Targeting Generates a High-Affinity Thrombin-Inhibiting Bivalent Aptamer. ChemBioChem, 8(18), 2223–2226. doi:10.1002/cbic.200700535
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.